Clinical Trials

Phase I Clinical Trial Completed

MenoGeniX has completed a multicenter, double-blind, randomized, placebo-controlled Phase I clinical trial that evaluated the safety and effectiveness of MNGX-100 in treating hot flashes in 30 women with naturally occurring or surgically induced menopause.

National Institute on Aging (NIA) of the National Institutes of Health (NIH) Funds Phase Ib/IIa Clinical Trial

In 2018, MenoGeniX received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) for the clinical development of MNGX-100 for the treatment of menopausal hot flashes. The grant funding will support a Phase Ib/IIa clinical trial evaluating the safety and efficacy of multiple doses of MNGX-100 in 60 women with naturally occurring or surgically induced menopause.

Phase Ib/IIa Clinical Trial

MenoGeniX is currently scaling up for it's clinical trial supported by the National Institute on Aging (NIA) of the National Institutes of Health (NIH) for the clinical development of MNGX-100 for the treatment of menopausal hot flashes. The grant funding will support a Phase Ib/IIa clinical trial evaluating the safety and efficacy of multiple doses of MNGX-100 in 60 women with naturally occurring or surgically induced menopause.